April 3, 2025 10:01 PM EDTUpdated 08:20 AM
Deals
China

F-star man­age­ment takes com­pa­ny pri­vate, two years af­ter $161M cash ex­it to Sino's in­voX

Kyle LaHucik

Senior Reporter

UK an­ti­body de­vel­op­er F-star Ther­a­peu­tics has be­come a pri­vate, in­de­pen­dent biotech.

The sur­prise move — an­nounced via F-star’s LinkedIn page on Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Kennedy team de­fends Marks fir­ing, while 20% of staff cuts may be 'mis­takes'

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

Re­lay Ther­a­peu­tics does third round of lay­offs in nine months, af­fect­ing about 70 em­ploy­ees

Arv­inas touts healthy vol­un­teer da­ta for Parkin­son's dis­ease PRO­TAC

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times